The MD Anderson Symptom Inventory Chronic Myeloid Leukemia Module (MDASI-CML)
|ORDER ASSESSMENT TOOLS|
MD Anderson Symptom Inventory (MDASI) modules augment the 19 core MDASI symptom and interference items with additional items identified as unique to a particular patient population. MDASI modules may be disease-specific, disease-site-specific, or treatment-specific.
The MDASI chronic myeloid leukemia module (MDASI-CML) is a site-specific module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-CML also assesses 7 chronic myeloid leukemia-specific symptom items: diarrhea, swelling, rash/skin change, muscle soreness/cramping, bruising/bleeding easily, malaise, and headache.
- Purpose: To assess the severity of multiple chronic myeloid leukemia-related symptoms and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by chronic myeloid leukemia and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
- Time required: Five minutes
- Scoring: Please see the MDASI User's Guide
- Reliability: Cronbach alpha reliability ranges from 0.91 to 0.94
MDASI-CML Language Versions
The MDASI-CML is available in the languages shown below. Click on a linked language to view a sample in PDF format.
|Psychometrically and Linguistically Validated||Linguistically Validated|
Chinese - Simplified
Portuguese - Portugal
Future Validation Studies: We would like to collaborate with other investigators to develop and validate new language versions of the MDASI-CML. Contact us for more information. NOTE: The MDASI-CML may not be modified or translated into another language without express written consent (see Notice of Copyright below).
To Order the MDASI-CML
|Type of Use||First Language Version (Per Project)||Additional Language Versions (Per Project)|
|Non-funded academic research||No charge||No charge|
|Individual clinical practice||No charge||No charge|
|Funded academic research||$300||$150|
The MDASI-CML will be e-mailed to you as a PDF file within 7 to 10 business days. If your request is urgent or the language version you seek is not shown, contact us to make special arrangements:
Department of Symptom Research
Attn: Assessment Tools
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 1450
Houston, Texas 77030
If applicable, an invoice will be e-mailed to you. Reference the invoice number on your payment and include on the memo line, "MD Anderson Assessment Tool Distribution."
The M. D. Anderson Symptom Inventory (MDASI) copyright is held by The University of Texas MD Anderson Cancer Center and administered by the MDASI's developer, Charles S. Cleeland, PhD. The copyright applies to the MDASI, its modules, and all its derivatives in any language.
The MDASI-CML may not be used or reproduced without permission from Charles S. Cleeland, PhD, or his designee. Fees for use may apply (see above).
The MDASI and its modules may not be modified or translated into another language without the express written consent of the copyright holder. Failure to comply may result in legal action. Contact us via e-mail at firstname.lastname@example.org or at the address shown above to obtain permission to alter or translate the instrument.
Williams LA, Garcia-Gonzalez A, Ault P, Mendoza TR, Cleeland CS, Mobley GM, Williams JL, Cortes JE. A new symptom measure in chronic myeloid leukemia [abstract]. American Society of Clinical Oncology 47th Annual Meeting, Chicago IL, Jun 3-7, 2011. J Clin Oncol 29(15 Suppl), 2011; e19545.
Williams LA, Cortes JE, Ault P, Garcia-Gonzalez A, Williams JL, Cleeland CS. Including patient input in patient-reported outcome instrument development: examples from the MDASI-CML [abstract]. American Society of Hematology 2010 Annual Meeting, Orlando FL, Dec 4-7, 2010. Blood 116(21): 1065, 2010; 2573.
Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle M, Morrissey M, & Engstrom MC. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer 89:1634-1646, 2000.
Williams LA, Ault P, Garcia-Gonzalez A, Huang F, Sailors MH, Cleeland CS, Cortes JE. Relationship of patient-reported symptoms to daily functioning in chronic myeloid leukemia [abstract]. American Society of Hematology 54th Annual Meeting and Exposition, Atlanta GA, Dec 8-11, 2012. Blood 118(21): 2012; 4260.
Williams LA, Jacobsen PB, Sailors MH, Phillips KM, Ault P, Garcia-Gonzalez A, Pinilla-Ibarz J, Cortes JE, Cleeland CS. Symptoms in chronic myeloid leukemia survivors on tyrosine kinase inhibitor therapy at two cancer centers [abstract]. Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) 2012 International Symposium on Supportive Care in Cancer, New York NY, Jun 28-30, 2012. Support Care Cancer 20(Suppl 1): S240, 2012; 1003.
Garcia-Gonzalez A, Ault P, Williams LA, Williams JL, Cleeland CS, Cortes JE. Interactive voice response system compliance in chronic myeloid leukemia population [abstract]. American Society of Clinical Oncology 48th Annual Meeting, Chicago IL, Jun 1-5, 2012; e19589.
Williams LA, Ault PS, Garcia-Gonzalez A, Shi Q, Williams JL, Cleeland CS, Cortes JE. Identifying high symptom burden in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy [abstract]. American Society of Hematology 53rd Annual Meeting and Exposition, San Diego CA, Dec 10-13, 2011. Blood 118(21): 1356, 2011; 3138.
Williams LA, Garcia-Gonzalez A, Ault P, Williams JL, Mobley GM, Mendoza TR, Cleeland CS, Cortes JE. Symptom burden in patients with chronic myeloid leukemia (CML) on kinase inhibitor (KI) therapy [abstract]. American Society of Hematology 2010 Annual Meeting, Orlando FL, Dec 4-7, 2010. Blood 116(21): 1570-1571, 2010; 3838.
Williams LA, Ault P, Cleeland CS, Reynolds RJ, Shah NA, Shah PK, Cortes JE. Symptom burden in chronic myeloid leukemia (CML) [abstract]. American Society of Clinical Oncology 2010 Annual Meeting, Chicago IL, Jun 4-8, 2010. J Clin Oncol 28(15 Suppl): 480s, 2010; 6133.
Symptom Research hosts national colloquium on developing strategies for reducing cancer treatment-related toxicities and symptoms. Read more...
Announcing the publication of Cancer Symptom Science, an interdisciplinary, first-of-its-kind compilation of research on the mechanisms underlying the expression of cancer-related symptoms. Read more...
Old Drugs, New Possibilities (Conquest, Fall 2008)
Symptom Research Awarded NIH P01 Grant (Division of Internal Medicine Newsletter, Summer 2008)
Symptom Research and Psychometrics (Network, Summer 2008)